Cleveland Clinic | Strategic Alliance Partners

April 06, 2023

Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.

April 05, 2023

Expert perspectives on how to identify and assess patients with myelofibrosis for transplant therapy.

April 05, 2023

Comprehensive discussion highlighting diagnostic and molecular testing involved in the diagnosis of myelofibrosis, challenges related to early diagnosis, and consideration factors for assessing prognostic risk.

April 05, 2023

A recent retrospective study found that patients with endometrial cancer in International FICO stage I high- intermediate risk subgroups with fewer than 2 risk factors had a greater than 95% cause-specific survival at 3-year follow-up, and subgroups with 2 or more risk factors had poorer outcomes.

April 03, 2023

Khaled Hassan, MD, discusses key results from the phase 1 CHRYSALIS trial of the bispecific antibody amivantamab-vmjw in non–small cell lung cancer expressing EGFR exon 20 insertion mutations.

March 30, 2023

Switching their focus to non-muscle-invasive bladder cancer (NMIBC), panelists identify the treatment armamentarium in this setting.

March 30, 2023

A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.

March 29, 2023

Shared insight on classification, risk factors, and important biomarkers and pathways in myelofibrosis.

March 29, 2023

Panel experts share insight regarding prognosis for patients with polycythemia vera and the associated risk for progression to myelofibrosis.

March 25, 2023

Craig Sauter, MD, discussed the common limitations of CAR T-cell therapy through timely referral and the existing questions for patients with LBCL who progress on CAR T-cell therapy.

March 23, 2023

A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.

March 23, 2023

A panel of four key opinion leaders share real-world urothelial carcinoma practice patterns at their respective institutions.

March 23, 2023

Cleveland Clinic has opened a new state-of-the-art cancer facility, named the Fatima bint Mubarak Center, at Cleveland Clinic Abu Dhabi.

March 22, 2023

A review of systemic treatment options used in polycythemia vera and the roles these play in the current treatment landscape.

March 22, 2023

A brief overview of myeloproliferative neoplasms and the associated signs and symptoms commonly presenting in patients.

March 14, 2023

Adjuvant osimertinib and other targeted therapies, such as KRAS G12C inhibitors, could continue to change the perioperative treatment landscape in non–small cell lung cancer.

March 14, 2023

Craig Sauter, MD, discusses where BTK inhibitors could fit into the frontline treatment landscape for patients with central nervous system lymphoma and research aiming to address other unmet needs for this patient population.

March 07, 2023

The advent of effective first-generation TKIs has allowed for improvements among patients with Philadelphia chromosome–positive disease, which is traditionally associated with a poor prognosis, as it generally does not respond to conventional chemotherapy options.

March 03, 2023

Khaled Hassan, MD, discusses the importance of performing precise molecular profiling in patients with lung cancer and the need to identify individually tailored treatment approaches.

February 28, 2023

To increase access to emerging cancer therapeutics and improve convenience for patients and researchers, Taussig Cancer Institute opened a dedicated Novel Therapeutics Clinic.